PositiveID's ExcitePCR Proposes
Use of its FireflyDX to Address Food Safety Testing Needs Revealed
in Blue Ribbon Study Panel on Defense of Animal Agriculture in
Interview with SmallCapVoice.com
ExcitePCR Chief Science Officer
Kimothy Smith, DVM, Ph.D. discusses utilizing ExcitePCR's FireflyDX
Products to Improve Pathogen and GMO Testing for the $19 Billion
Global Food Safety Testing Market
Austin TX -- October 26, 2017 -- InvestorsHub NewsWire --
SmallCapVoice.com, Inc. and PositiveID Corporation ("PositiveID" or
"Company") (OTC:
PSID), a life sciences company focused on detection and
diagnostics, today announced a new audio interview with Kimothy
Smith, DVM, Ph.D., Chief Science Officer of PositiveID's ExcitePCR
subsidiary. In the interview, Smith discusses the recently released
"Blue Ribbon Study Panel on Biodefense: Defense of Animal
Agriculture," and describes how ExcitePCR's FireflyDX products
could help address the needs of the $19 billion global food safety
testing market. The interview can be heard at: http://smallcapvoice.com/blog/10-25-17-smallcapvoice-interview-with-positiveid-corporation-psid.
As highlighted in a recently published "Blue Ribbon Study Panel
on Biodefense: Defense of Animal Agriculture," "The increasing rate
of emerging and reemerging zoonotic disease, along with threats and
attempts by those with nefarious intent to attack food and
agriculture, point to the need to exert more effort to eliminate
vulnerabilities and reduce consequences associated with America's
agricultural sector." Smith explains that FireflyDx will have
applications to food safety and agricultural defense, among others,
and could be used pen-side by veterinarians and animal health
technicians diagnosing routine infectious diseases or during a
severe outbreak of disease whether naturally occurring or as a
result of agro-terrorism.
The FireflyDX products, currently under development, include the
FireflyDX-Portable and FireflyDX-Handheld, and are designed for use
in markets where molecular diagnostics are critical to ensure rapid
safety and treatment protocols. FireflyDX has already proven its
ability in the lab to detect various pathogens that are a threat to
food safety including common food contaminants such as E. coli
O157, animal diseases caused from Anthrax, Plague, and Brucellosis,
and a genetically modified organism (GMO) biomarker, which is
critical to the corn and soybean export markets.
Existing solutions for accurately identifying potential
pathogens and bio-threats, especially at the point-of-care or
point-of-need, can sometimes take as long as several hours to
several days to provide results, dramatically delaying what is
often life-saving treatment, while also increasing costs, both
personal and financial. In addition, most state-of-the-art
polymerase chain reaction (PCR) solutions in use today for pathogen
detection typically require a professionally trained operator
working in a pristine laboratory setting and/or are heavy, bulky
and require a personal computer to function properly. The FireflyDX
products are designed to eliminate many of the challenges faced by
existing, lab-based PCR systems.
According to a report from Global Industry Analysts, Inc., the
global market for Food Safety Testing is projected to reach US$19.7
billion by 2018, driven by the continuous rise in the product
recalls due to contamination by bacteria and other micro-organisms,
rising awareness about the harmful effects of consuming
contaminated food, and implementation of stringent regulatory
specifications.
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations
firm, with clients nationwide, known for its ability to help
emerging growth companies build a following among retail and
institutional investors. SmallCapVoice.com utilizes its stock
newsletter to feature its daily stock picks, audio interviews, as
well as its clients' financial news releases. SmallCapVoice.com
also offers individual investors all the tools they need to make
informed decisions about the stocks they are interested in. Tools
like stock charts, stock alerts, and Company Information Sheets can
assist with investing in stocks that are traded on the OTC BB and
Pink Sheets. To learn more about SmallCapVoice.com and their
services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/.
About ExcitePCR
Headquartered in Pleasanton, California, ExcitePCR Corporation
is developing portable pathogen detection systems based upon
superior sample preparation and realtime PCR (Polymerase Chain
Reaction) methodologies. Its FireflyDX technologies will deliver
rapid automated Point-of-Care/Point-of-Care (POC/PON) sample
preparation and highly accurate biohazard identification in a
fraction of the time currently possible using existing PCR-based
solutions.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics
company with an extensive patent portfolio. PositiveID develops
biological detection and diagnostics systems, specializing in the
development of microfluidic systems for the automated preparation
of and performance of biological assays. PositiveID is also a
leader in the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or
connect with PositiveID on Twitter, Facebook or LinkedIn.
On August 24, 2017, PositiveID Corporation and its wholly-owned
subsidiary PositiveID Diagnostics, Inc. (collectively, the
"Seller"), entered into an Asset Purchase Agreement ("APA") with
ExcitePCR Corporation. Pursuant to the APA, at closing, the Seller
will sell and deliver to ExcitePCR all assets used in connection
with the operation of the FireflyDX technology. For more
information on the APA, please read PositiveID's Form 8-K filed on
August 28, 2017, which can be found here.
Statements about PositiveID's future expectations, including the
likelihood that the company plans to use FireflyDX to address food
safety testing needs; the likelihood that the Company will utilize
ExcitePCR's FireflyDX products to improve pathogen and GMO testing
for the $19 billion global food safety testing market; the
likelihood that the FireflyDX products could help address the needs
of the $19 billion global food safety testing market; the
likelihood that Firefly Dx will have applications to food safety
and agricultural defense, among others, and could be used pen-side
by veterinarians and animal health technicians diagnosing routine
infectious diseases or during a severe outbreak of disease whether
naturally occurring or as a result of agro-terrorism; the
likelihood that the global market for food safety testing is
projected to reach US$19.7 billion by 2018, driven by the
continuous rise in the product recalls due to contamination by
bacteria and other micro-organisms, rising awareness about the
harmful effects of consuming contaminated food, and implementation
of stringent regulatory specifications; constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Litigation Reform Act of 1995.
Such forward-looking statements involve risks and uncertainties and
are subject to change at any time, and PositiveID's actual results
could differ materially from expected results. These risks and
uncertainties include, without limitation, the Company's ability to
complete the development and testing of the FireflyDX products; the
Company's ability to raise capital; the Company's ability to
commercialize the FireflyDX products; the Company's and ExcitePCR's
ability to close the APA; as well as other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings
with the Securities and Exchange Commission, including those set
forth in the Company's 10-K filed on March 31, 2017, and 10-Qs
filed on August 14, 2017, May 15, 2017, and November 18, 2016,
under the caption "Risk Factors." The Company undertakes no
obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Contact for PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Contact for SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com
Source: SmallCapVoice.com